LKT Labs

Biochemicals for Life Science Research

AZD-1152-HQPA

AZD-1152-HQPA

Product ID A9714
Cas No. 722544-51-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $86.90 Please Inquire
5 mg $160.50 Please Inquire
10 mg $260.80 Please Inquire
Bulk Quote

Quicklinks

Description

AZD-1152-HQPA inhibits aurora kinases B and C (AurB, AurC), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for cancers with solid tumors. In acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cells, AZD-1152-HQPA induces apoptosis, inhibiting proliferation. AZD-1152-HQPA also induces apoptosis in glioma cells, inhibiting proliferation in vitro and tumor growth in vivo.

Product Info

Cas No.

722544-51-6
Purity

≥98%
Formula

C26H30FN7O3
Formula Wt.

507.56
IUPAC Name

2-[3-[[7-[3-[ethyl(2-hydroxyethyl)amino]propoxy]quinazolin-4-yl]amino]-1H-pyrazol-5-yl]-N-(3-fluorophenyl)acetamide
Synonym

AZD1152-HQPA
Solubility

DMSO 102 mg/mL (200.96 mM) Ethanol 3 mg/mL (5.91 mM) Water Insoluble
Appearance

Off-white Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

A9714 MSDS PDF
Info Sheet

A9714 Info Sheet PDF

References

Hartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013 Mar;27(3):560-8. PMID: 22940834.

Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012 Jul;108(3):349-60. PMID: 22382783.

Boss DS, Witteveen PO, van der Sar J,et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011 Feb;22(2):431-7. PMID: 20924078.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C0153

    Calcitonin, rat

    Endogenous neuropeptide hormone, lowers extracellu...
    ≥95%
  • F6803

    FRAX486

    PAK inhibitor.Smo inhibitor.
    ≥98%
  • E6397

    EPZ6438

    EZH2 HMT inhibitor. It induces regression in malig...
    ≥99%
  • S8245

    Sulfadiazine

    Sulfonamide; folate production inhibitor.
    ≥98%
  • M0262

    Maprotiline Hydrochloride

    Tetracycline; FIASMA, histamine H1, 5-HT2, mAChR, ...
    ≥98%
  • L2540

    LGK-974

    PORCN inhibitor.
    ≥98%
  • C0027

    Cafestol Linoleate

    Diterpene found in brewed, unfiltered coffee; FXR ...
    ≥98%
  • M3408

    [D-Asp3]-Microcystin-LR

    Cyclic heptapeptide produced by Microcystis; PP1/2...
    ≥95%
  • W0272

    S-(−)-Warfarin >99

    Coumarin, more potent isomer; VKORC1 inhibitor.
    ≥98%
  • P0007

    Pituitary Adenylate Cyclase-activating Polypeptide (6-27), human, sheep, rat

    Endogenous peptide, involved in paracrine and auto...
    ≥95%
  • C1624

    Cefuroxime Sodium

    β-lactam; penicillin binding protein inhibitor.
    ≥98%
  • N8561

    NVP-AEW541

    IGF-1R inhibitor.
    ≥98%
  • D0353

    Danofloxacin Mesylate

    Fluoroquinolone; bacterial DNA gyrase inhibitor.
    ≥98%
  • C3251

    Cinnarizine

    FIASMA, L-type Ca2+ channel blocker, D2 antagonist...
    ≥98%
  • E6256

    Epothilone A

    Microtubule depolymerization inhibitor.
    ≥95%
  • A0402

    Abacavir Sulfate

    Nucleoside (guanosine) analog; RT, guanylyl cyclas...
    ≥98%
  • G4484

    Glucagon-like Peptide II, rat

    Endogenous peptide hormone, involved in intestinal...
    ≥95%
  • C0156

    9-Nitro-20S-camptothecin

    Camptothecin derivative; topoisomerase I inhibitor...
    ≥98%
  • D5898

    Doxycycline Monohydrate

    Tetracycline; protein translation inhibitor, MMP i...
    ≥97%
  • B3210

    R-Bicalutamide

    AR antagonist.
    ≥98%